Imagine a future where cutting-edge cancer treatments are developed and tested right on a university campus, offering new hope to patients. That future is now a reality at the University of Missouri, where a groundbreaking clinical trial has just begun, marking a significant milestone in the fight against cancer. But here's where it gets even more exciting: this trial isn't just about testing a new therapy—it's about showcasing the university's unparalleled ability to take a radiopharmaceutical from concept to patient care, all under one roof.
In a bold move, the University of Missouri's School of Medicine and MU Health Care have launched their first on-campus radiopharmaceutical clinical trial, leveraging the university's research reactor to manufacture a leading-edge therapy. This initiative not only highlights the institution's research prowess but also underscores its commitment to advancing cancer care. The trial, conducted in collaboration with ABK Biomedical, focuses on Eye90 microspheres®, a revolutionary treatment for unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
And this is the part most people miss: The University of Missouri Research Reactor (MURR) is the sole domestic source of yttrium-90 (Y-90), the radioisotope embedded in these microspheres. This unique capability allows Mizzou to play a pivotal role in developing and producing innovative cancer therapies. The trial's first patient was enrolled at MU Health Care's Ellis Fischel Cancer Center, with treatment commencing on February 9, marking a major step forward in the university's expansion into radiopharmaceutical clinical trials, supported by the NextGen Precision Health initiative.
“This clinical trial is a testament to the power of our campus research,” said Mun Choi, President of the University of Missouri. “With the nation’s largest university research reactor and unmatched facilities in veterinary medicine, our School of Medicine, and NextGen Precision Health, we’re uniquely positioned to partner with industry leaders. This collaboration accelerates the development and testing of groundbreaking treatments, bringing them to patients faster—all from one campus.”
Eye90 microspheres stand out due to their innovative design. These radiopaque glass beads, embedded with Y-90, are engineered for precise visualization during delivery, enabling interventional radiologists and oncologists to target liver tumors with localized radiation therapy. This approach aims to maximize treatment efficacy while minimizing damage to surrounding healthy tissue—a game-changer for patients with limited treatment options.
“Participating in this trial is a significant milestone for Ellis Fischel,” noted Ryan Davis, associate professor of clinical radiology and on-site study coordinator. “It not only provides our patients with early access to potentially life-changing therapies but also reinforces our leadership in translational research. Targeted radiotherapy is becoming increasingly important for metastatic tumors, and we’re thrilled to be at the forefront of this advancement.”
But here's the controversial part: While the potential of Eye90 microspheres is undeniable, questions remain about their long-term efficacy and accessibility. Will this therapy become widely available, or will it remain out of reach for many patients? And how will it compare to existing treatments in terms of cost and outcomes? These are the debates that could shape the future of cancer care.
Mizzou’s role in this trial builds on decades of pioneering work in Y-90 therapy. Since the 1980s, the university has been a leader in developing and producing glass microspheres, culminating in the FDA approval of TheraSphere in 2021. MURR remains the only U.S. producer of these microspheres, a distinction that highlights its critical role in advancing nuclear medicine.
For the Eye90 project, ABK Biomedical partnered with MURR to irradiate and process the microspheres on-site, ensuring a reliable supply for preclinical and clinical trials. Mizzou researchers also conducted the safety and efficacy studies that paved the way for the human clinical trial. Jeffrey Bryan, professor of oncology in Mizzou’s College of Veterinary Medicine, led initial studies in small animal models and a clinical trial in dogs with hepatocellular carcinoma, demonstrating the treatment’s effectiveness and safety.
Looking ahead, the Mizzou clinical trial is part of a larger effort to evaluate Eye90 microspheres in patients with unresectable liver tumors. The study involves a single administration of the microspheres, followed by a year-long monitoring period to assess tumor response and quality of life. ABK Biomedical has initiated similar studies globally, with the first patient treated at Auckland Hospital in New Zealand, aiming to gather data for regulatory approvals and broader clinical adoption.
As Mizzou and Ellis Fischel continue to pioneer advanced treatments, they remain committed to improving patient care through cutting-edge research and collaboration. This trial is not just a scientific achievement—it’s a beacon of hope for cancer patients worldwide.
Now, we want to hear from you: Do you think on-campus manufacturing of radiopharmaceuticals could revolutionize cancer treatment? What are your thoughts on the accessibility and affordability of such therapies? Share your opinions in the comments below and join the conversation!
